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Jan J van Wingerden1*, Dirk T Ubbink2, Chantal MAM van der Horst1 and Bas AJM de Mol3Abstract
Early recognition and, where possible, avoidance of risk factors that contribute to the development of poststernotomy
mediastinitis (PSM) form the basis for successful prevention. Once the presence of PSM is diagnosed, the known risk
factors have been shown to have limited influence on management decisions. Evidence-based knowledge on treatment
decisions, which include the extent and type of surgical intervention (other than debridement), timing and others is
available but has not yet been incorporated into a classification on management decisions regarding PSM. Ours is a first
attempt at developing a classification system for management of PSM, taking the various evidence-based reconstructive
options into consideration. The classification is simple to introduce (there are four Types) and relies on the careful
establishment of two variables (sternal stability and sternal bone viability and stock) prior to deciding on the best
available reconstructive option. It should allow better insight into why treatment decisions fail or have to be altered and
will allow better comparison of treatment outcomes between various institutions.
Keywords: Classification, Infection, Mediastinitis, Mediastinal infection, Outcomes, Poststernotomy, Postoperative, Sternal
infection, Wound infectionIntroduction
Poststernotomy mediastinitis (PSM) is still one of the
most complex and costly infectious processes to treat.
Changes in cardiac surgical patient population and con-
tributing pathogens, amongst others, have ensured that
the incidence of PSM, despite many advances in preven-
tion, remains significant.
Data recently presented by the Netherlands Associ-
ation for Cardio-Thoracic Surgery, which includes all 16
cardiac surgical centers, showed an increase in open car-
diac procedures between 2007 and 2011 from 15 500 to
16 500 per year [1]. Data procured from 8 of the 16 cen-
ters from 2002 to 2007 revealed a cumulative incidence
for surgical site sternal wound infection of 2.4% (95% con-
fidence interval [CI], 1.9 to 3.1) following coronary ar-
tery bypass grafting (CABG) [2]. This figure rose to
3.2% (95% CI, 2.0 to 5.1) where CABG was combined* Correspondence: j.j.vanwingerden@amc.uva.nl
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article, unless otherwise stated.with concomitant valve surgery. This roughly translates
to 396 to 530 new cases a year. Between hospitals, the
adjusted rates varied from 0.0% to 9.7% [2]. By compari-
son, in the United States approximately 700,000 median
sternotomies are performed each year, leading to nearly
8,300 cases of deep sternal wound infections [3].
The acute mortality rates in some large centers still
approach 40% internationally [4]. Even if the patient sur-
vives, the long-term mortality rate is significantly higher.
In a 10-year follow-up study after CABG [5], the ad-
justed survival rate was 39% for patients who had suf-
fered from PSM compared with 70% who did not. The
adjusted hazard ratio for mortality during that period
was 2.12 (95% CI, 1.80 to 2.49; P < 0.001). The study by
Graf and colleagues [4] confirmed the findings of an
earlier study from Uppsala, Sweden [6], with a similar
length of follow-up.
PSM has a significant impact on both healthcare and
hospital budgets. In a recent case-control study performed
by Graf and colleagues [4] from Hannover, Germany, theCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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(P < 0.0001) and the median length of stay more than dou-
bled (P = 0.0006). Ennker and colleagues [7] demon-
strated an opportunity cost, or turnover increase, in
excess of 10 600 euro through reducing the average
hospitalization of their PSM patients from 48,43 to
36,73 days by improving treatment efficiency.
The enormous amount of intellectual investment re-
quired from a multidisciplinary team including, among
others, microbiologists, intensivists, radiologists, cardi-
ologists, cardiothoracic and plastic surgeons in effect-
ively dealing with these cases has yet to be calculated.
Recent developments such as the introduction of top-
ical negative pressure therapy (TNP), new insights into
the timing of flap surgery and flap choice, design and
methods of harvesting have all become significant in re-
cent years. Further improvement in the treatment and
research of PSM requires a targeted approach. A new,
evidence-based classification may allow for better com-
parison between different treatment protocols and may
further both research and refinement in the manage-
ment of PSM.
The aim of this paper is to categorize and assess the
effectiveness of a range of primary and secondary recon-
structive management options for PSM, based on cur-
rently available evidence and present an evidence-based
classification. See the “Clinical definition of PSM”.
Clinical definition of poststernotomy mediastinitis
(van Wingerden JJ, de Mol BAJM, van der Horst CMAM:
Poststernotomy mediastinitis: definition and
terminology, Submitted)
Poststernotomy mediastinitis (in adults) must meet the
following criteria:
Infection occurs within 1 year, regardless of whether an
implant is in place or not
AND infection appears related to the operative
procedure
AND, at least 1 of the following criteria:
1. Patient has organisms cultured from mediastinal
tissue or fluid obtained during a surgical operation
or needle aspiration.
2. Patient has evidence of mediastinitis seen during a
surgical operation or histopathologic examination.
3. Patient has at least 1 of the following signs or
symptoms with no other recognized cause: fever
(>38 0C), chest pain, or sternal instability
AND at least 1 of the following:
a. Purulent discharge from mediastinal area
b. Organisms cultured from blood or spontaneous
discharge from mediastinal area
c. Radiological evidence of an infective process in
the mediastinum.Methods
Literature search strategy
A search of the literature from 1990 to March 2014 was
conducted without language restrictions using the
Cochrane Central Register of Controlled Trials, Ovid
Medline, and PubMed and Web of Science databases.
Key words and MeSH terms were used to identify and a
manual search of the reference lists was done regarding
all possible factors (excluding pre-, or intra-operative
risk factors) that could influence the current treatment
decisions of PSM. Only procedures for which either
usefulness or efficacy was claimed were considered.
The quality and strength of the evidence was weighed
according to the Rating Scheme used by the Society of
Thoracic Surgeons (STS) Workforce on Evidence-based
Medicine (EBM) for Classification of Recommendation
(see below) [8]. Two hundred thirty three records were
identified. Two members (JJvW & DU) reviewed titles
and abstracts to exclude records that were of interest.
In addition, a manual search of the reference lists
was done.
STS workforce on EBM rating scheme to assess the
quality and strength of the evidence
Rating Scheme for the Strength of the Evidence
Levels of Evidence
Level A. Data derived from multiple randomized
clinical trials.
Level B. Data derived from a single randomized trial
or from nonrandomized trials.
Level C. Consensus expert opinion.
Rating Scheme for the Strength of the
Recommendations
Classification of Recommendations
Class I. Conditions for which there is evidence or
general agreement, or both, that a given procedure is
useful and effective.
Class II. Conditions for which there is conflicting
evidence or a divergence of opinion, or both, about
the usefulness/efficacy of a procedure.
Class IIa. Weight of evidence favors usefulness/
efficacy.
Class IIb. Usefulness/efficacy is less well established
by evidence.
Class III. Conditions for which there is evidence or
general agreement, or both, that the procedure is not
useful/effective.
The Level of Evidence was independently established
by two authors (JJvW & DU) and a Classification of Rec-
ommendation was set by mutual consent. In case of dis-
agreement, a third reviewer (either BdM or CvdH) was
consulted.
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Search results
From two hundred thirty three records, the search strat-
egy rendered 78 studies, of which 4 were case reports
(Table 1) that complied with the selection criteria set
out above. Our literature search did not yield any man-
agement choices for which multiple randomized clinical
trials existed.
Classification of the studies found
As a result most studies were categorized as class II
(where evidence about the usefulness/efficacy of a proced-
ure is conflicting or opinion diverged, or both) per proced-
ure, while procedures for which no evidence existed were
discarded.
The type of study determined the level of evidence for
a specific procedure. Systematic reviews of observational
studies, controlled clinical trials, or comparable cohort
studies were considered to be Level B1 and case series
and regression analyses as B2. The Level of Evidence for
Case Reports was considered to represent Level C.
The outcome of the categorization of the supporting
literature is summarized in the Table 1. This shows that
the majority of studies with a Level B1 evidence led to a
Class IIa categorization and the majority of Level B2
studies resulted in a Class IIb categorization.
Harmonization
The new classification was based on the Level of Evi-
dence for the usefulness or effectiveness of a specific
management procedure as well as sternal stability, viabil-
ity, and available bone stock, together with timing of re-
construction. This resulted in a classification presented
in Table 2, describing the major types of management
strategies for four different clinical circumstances.
Review
Evidence found for the four major types of management
strategies
Type I
When minimal bone loss and a relatively stable sternum
are found at debridement, available evidence favors wound
management through the application of TNP. Microbial
identification and antibiotic susceptibility should be estab-
lished early. In addition, the dosing of antimicrobial agents
should be adjusted in obese patients to ensure adequate
tissue levels [9] (class I, level B) Evidence also suggests the
need for dosing adjustment following skeletonized IMA
harvesting as this significantly diminishes antimicrobial
penetration into the presternal tissue following IMA har-
vesting [10] (class IIa, level B1).
Evidence-based support for TNP therapy has been
provided by systematic reviews [11,12] and two meta-
analyses [13,14]. Prospective and retrospective clinicalstudies from our institution [15,16] and many others
[17-22], paralleled by meticulous in vitro studies de-
signed to determine the effect of TNP on the intratho-
racic organs [23-25], lend convincing evidence to claims
of efficacy and safety. Early diagnosis [26] and early ap-
plication of TNP therapy [27] seem to predict a greater
likelihood of survival (class IIa, level B2).
According to two recent studies [28,29], methicillin-
resistant Staphylococcus aureus (MRSA), as the primary
causative pathogen, is not a contraindication for TNP ther-
apy. (class IIa, level B) Negative-pressure therapy was also
successfully applied as a temporizing measure prior to sec-
ondary closure in candidal mediastinitis [30,31] (class IIb,
level B2 & C).
Severe bleeding, one of the most serious complications
during TNP therapy, fortunately occurs seldom [32,33].
As neither the frequency nor severity of bleeding ex-
ceeds that of the other conservative treatment modal-
ities, the same precautions should be taken to prevent it
during TNP therapy [33].
The current evidence supports the use of TNP, either
as a destination or as a bridge prior to final surgical clos-
ure (class I, level B).
Type 2
In Type 2 there is sufficient bone stock and the sternum
is relatively stable. Direct closure, usually accompanied
by advancement of the pectoralis muscle, is done either
primarily (without a conservative management bridge
such as TNP) (Type 2a) or delayed (Type 2b).
A single-stage procedure (Type 2a), combining drainage
and debridement with immediate flap reconstruction, was
favored by early workers in the field. Although never speci-
fied, two possible reasons justified this approach at that
time: first, the introduction of flap reconstruction which
dramatically decreased mortality related to PSM; and sec-
ondly, the high failure rate related to conservative manage-
ment such as packing and or antibiotic irrigation. This was
prior to the introduction of TNP therapy. In the advent of
very early diagnosis and referral, in the hemodynamically
stable patient or where TNP therapy is not available, im-
mediate flap closure may still be justified, as some have
pointed out [34-36] (all, class II, level B).
Alternatively, delayed closure (Type 2b) has gained
strong advocates in recent years for the following
reasons:
➣ improved accuracy in assessing the extent of the
sternal infection [37]
➣ improved outcome if flap closure is delayed until the
patient is hemodynamically stable [38,39]
➣ less risk of sepsis in high-risk patients [40,41]
➣ significant decrease in frequency and severity of
wound complications [42], including recurrence [40]
Table 1 Classification of recommendation and level of





Falagas et al. (2010) I B
Lancet, Great Britain [9]
Andreas et al. (2013) IIa B1
Ann Thorac Surg, Austria [10]
Segers et al. (2006), IIa B2
Thorac Cardiovasc Surg, Netherlands [16]
Bapat et al. (2008) IIb B2
J Card Surg, UK [20]
Vos et al. (2012), IIa B2
Interact Cardiovasc Thorac Surg,
Netherlands [21]
Sjögren et al. (2008), IIb B2
Int Wound J, Sweden [26]
Atkins et al. (2011) IIa B2
Am J Surg, USA [27]
Morisaki et al. (2011) IIa B2
Gen Thorac Cardiovasc Surg, Japan [28]
De Feo et al. (2010) IIa B1
Asian Cardiovasc Thorac Ann, Italy [29]
Modrau et al. (2009) IIb B2
Ann Thorac Surg, Denmark [30]
Osada et al. (2012) IIb C
Interact Cardiovasc Thorac Surg, Japan [31]
Ascherman et al. (2004) IIb B2
Plast Reconstr Surg, USA [34]
Cabbabe et al. (2009) IIa B1
Plast Reconstr Surg, USA [35]
Jang et al. (2012) IIb B2
Arch Plast Surg, Korea [36]
Agarwal et al. (2005) IIb B2
Plast Reconstr Surg, USA [43]
Cowan et al. (2005) IIb B2
Ann Thorac Surg, Canada [44]
Gaudreau et al. (2010) IIb B2
Eur J Cardiothorac Surg, Canada [45]
Gdalevitch et al. (2010) IIb B2
J Plast Reconstr Aesthet Surg, Canada [47]
Gustafsson et al. (2002) IIb B2
J Thorac Cardiovasc Surg, Sweden [48]
Danner et al. (2011) IIb B2
Thorac Cardiovasc Surg, Germany [50]
Risnes et al. (2012) IIa B1
Int Wound J, Norway [54]
Table 1 Classification of recommendation and level of
evidence of the selected literature (Continued)
Deschka et al. (2013) IIb B2
Interact cardiovasc Thorac Surg, Germany [55]
Baillot et al. (2010) IIa B1
Eur J Cardiothorac Surg, Canada [56]
Huh et al. (2008) IIb B2
J Thorac Cardiovasc Surg, USA [57]
Fawzy et al. (2011) IIb B2
J Cardiothorac Surg, Canada [58]
Sansone et al. (2011) IIb B2
J Card Surg, Italy [59]
Rocco et al. (2010) IIb C
Ann Thorac Surg, Italy [60]
Ceresa et al. (2010) IIb C
J Cardiothorac Surg, Italy [61]
van Wingerden et al. (2011) IIb B1
Interact Cardiovasc Thorac Surg,
Netherlands [69]
Milano et al. (1999) IIa B1
Ann Thorac Surg, USA [77]
Chittithavorn et al. (2011) IIb B2
Interact Cardiovasc Thorac Surg,
Thailand [78]
Hirata et al. (2003) IIb B2
Ann Thorac Surg, Japan [79]
Pasic et al. (2004) IIb C
Eur J Cardiothorac Surg, Germany [80]
Francel et al. (2001) IIa B1
Ann Thorac Surg, USA [81]
Stump et al. (2010) IIb B1
Ann Plast Surg, USA [82]
Parissis et al. (2011) IIb B2
J Cardiothorac Surg, UK [83]
Kobayashi et al. (2011) IIa B1
J Cardiothorac Surg, Japan [84]
Quality and strength of the Evidence weighed according to the STS Workforce
on EBM Rating Scheme (see above). The Level of evidence is subdivided
whereby B1 represents systematic reviews from observational studies,
controlled clinical trials and comparable cohorts. B2 represents case series and
regression analyses. Case reports were allocated to Level C.
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debridement and closure has become less of a hazard
since the application of, and the experience gained with,
TNP therapy. A body of current literature supports the
findings from our institution [16] that early diagnosis
and immediate application of TNP therapy will allow
healing without further ado in a substantial number of
patients [21,43,44] (all, class II a, level B2).
Table 2 AMSTERDAM classification (Assiduous Mediastinal Sternal Debridement & Aimed Management)
Type Sternal stability Bone viability & stock Reconstruction Staging of reconstruction
1 Stable Reasonable TNP (class I, level B)
2a Local muscle flap* Primary
(class II, level B)
2b Muscle** or Omentum flap Delayed
(class I, level B).
3a Unstable Viable & sufficient Rewiring/osteosynthesis Primary#
Delayed^
(class IIb, level B)
3b Rewiring/osteosynthesis Primary#
Delayed^and
Muscle** or Omentum flap (class IIb, level B)
4a Necrotic & insufficient Muscle flap Primary/ Delayed
4b Omentum flap (class IIb, level B)
4c Muscle and Omentum flap
*Always, unilateral or bilateral pectoralis muscle advancement.
**Frequently, unilateral or bilateral pectoralis muscle advancement.
#Rewiring.
^Osteosynthesis (plates, clips, etc.).
Important: When definite reconstruction is “delayed”, time interval and temporizing procedure (e.g. TNP) should be specified.
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64.9%) required some sort of direct secondary closure,
with or without the aid of a flap [15] (class IIa, level B2).
Whereas early diagnosis [26] (class IIb, level B2) and the
application of TNP therapy [27] (class IIa, level B2) pre-
dicts a greater likelihood of survival (class II, level B), pro-
longed TNP therapy was shown to be a significant
independent predictor of late mortality [26] (OR, 1.13;
95% CI, 1.05 to 1.21; P = 0.001) (class IIb, level B2). Fur-
thermore, two studies [20,45] suggest that prolonged ap-
plication of TNP therapy can result in recurrent problems
due to chronic infection (class IIb, level B2). This could
perhaps be explained, to some extent, that TNP therapy is
known to be accompanied by a significant shift in bacterial
species – even increased growth of some, such as S. aur-
eus – instead of a reduction in bacterial load [46].
The real challenges related to the treatment of PSM
with TNP therapy thus lie first in timely diagnosis and
application, and secondly in deciding when to stop TNP
therapy altogether and continue with further surgical re-
construction. Some insight may be gained by looking at
a retrospective cohort study by Gdalevitch and col-
leagues [47]. Defining TNP therapy failure as death
from sepsis, a need for surgical closure or recurrence of
infection within 1 year, they found bacteremia to be the
most sensitive predictor (sens. = 87.5) and a wound
depth of >4cm (spec. =89.9) followed by the degree of
sternal exposure and instability (spec. =85.7) to be the
most specific predictors of failure. (class IIb, level B2)
Gustafsson [48] and others [49] have been guided by
plasma C-reactive protein levels (<30–70 mg/L), whileothers have suggested that three consecutive negative
wound and tissue cultures are more reliable predictors
[45] (all class IIb, level B2). The necessity for obtaining
negative cultures has been questioned by two very recent
studies [50,51], which found that the presence of positive
tissue cultures at the time of closure does not influence
the rate of readmissions for recurrent infection.
In the Type 2b and all other types where definite closure
is delayed, early commencement and limiting duration of
TNP may offer a better outcome (class I, level B). There
are inconclusive data regarding determining optimal tim-
ing of closure (class IIa, level B).
Type 3
In Type 3 and Type 4, the sternum is unstable. The via-
bility and amount of remaining sternal bone following
debridement(s) distinguish them. With sufficient bone
stock left, the sternal stability is aided by rigid fixation with
wires, plates or clips – without flap coverage [52,53] (Type
3a) or with it (Type 3b). Two studies have recently com-
pared rewiring and suction–irrigation with other modal-
ities of treatment. Less frequent sternal wound healing
failure or re-infection has been reported in a cohort
treated by TNP and rewiring (6%), when compared with
the rewiring and suction–irrigation drained cohort (21%;
RR, 0.29; 95% CI, 0.06 to 0.88; P = 0.01) [54]. In approxi-
mately 14–15% of patients an additional muscle flap re-
construction was done. The other study compared the
outcome following rewiring and suction–irrigation drain-
age with rewiring only [55]: in 74% of patients rewiring
with suction–irrigation sufficed, vs. 59% of the rewiring-
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dence suggests that the outcome following rewiring-only
could be worse when compared to rewiring and suction-
irrigation drainage (combined), whereas the latter may be
less advisable than combining TNP with rewiring. (class
IIb, level B2) Flap coverage may be effective following wir-
ing (Type 3b) but the data are inconclusive. It is recom-
mended where the surgeon considers this necessary (class
IIb, level B).
Following plating, flap coverage with either bilateral pec-
toral muscle advancement flaps [45,56-58] or omentum
[59-61] is recommended (class IIb, level B2). Despite this
precaution, recurrence of infection, necessitating plate re-
moval, has been reported in 5–10% of cases [45,58]. In all
patients the sternum remained stable following plate re-
moval because of a recurrent infection.
More recently, the successful use of clips, either of ther-
moreactive nickel-titanium [62] or titanium only [63], in-
stead of plates, has been reported. Titanium alone,
contrary to the impression given by some [58] may not be
sufficiently bacteriostatic [64]. Attractive future prospects
include coatings for the titanium either with anti-adhesive
properties to prevent adhesion-mediated bacterial (par-
ticularly Staphylococcal) anchorage and biofilm produc-
tion [64], or for controlled release of antimicrobials such
as antibiotics [65], antimicrobial peptides [66] or their syn-
thetic analogues [67].
Type 4
Type 4 is recognized by loss of sternal stability and vi-
able bone. Soft-tissue (flap) reconstruction following de-
bridement of all necrotic and fractured bone improves
local vascularity, can obliterate dead space and, on its
own (without additional fixation), may ensure sufficient
chest stability [68] in these cases. Type 4a represents
muscle flap closure, the commonest being pectoralis,
rectus abdominis and the two combined, or latissimus
major muscle. Bilateral pectoralis muscle flaps, as either
advancement or turnover flaps, remain the most popular
“single type” muscle flaps [69]. Favoring a muscle flap
above an omental flap has two lesser-known disadvan-
tages: a slight survival disadvantage (overall RR 1.29;
95% CI, 0.58 to 2.88) [70] (class IIb, level B1) and pos-
sible association with more, and more frequent, compli-
cations when compared with omental flaps [27,69].
As a better understanding regarding angiogenesis [70,71],
antimicrobial activity [72] and tissue-generation promotion
[73] by the omentum emerges, so does the popularity of a
single omental flap (Type 4b) in the treatment of PSM rise.
Harvested either laparoscopically [49,74], by laparotomy or
manually, transdiaphragmatically [3], it is particularly pre-
ferred following significant sternal loss, where bulk is re-
quired to fill the dead space. Contrary to the fear of
postfilling atrophy expressed [75], the omentum has beenshown to hypertrophy when a Burgundian lifestyle is em-
braced following successful transfer for PSM [76].
A clear preference has been expressed for the use of
omentum (instead of muscle) in cases where the primary
causative organism is particularly resistant, such as
MRSA [50,77-80] (class IIb, level B2) or Candida [31,81]
(class IIb, level C & class IIa, level B1, resp.) or where
the patient suffers from diabetes mellitus [82] (class IIb,
level B1). The omental flap is transposed either delayed
or, less frequently, as part of the primary procedure.
In Type 4c both the omentum and pectoralis major
muscle advancement are transferred [83,84] (class IIb,
level B2 & class IIa, level B1, resp.).
Discussion
This study shows that, by careful application of the rating
scheme recommended by the respected STS workforce on
EBM, none of the current reconstructive options, with a
few exceptions (case reports), available to the surgical
team reaches a level of evidence higher than B. This
means that data were derived from either a single random-
ized trial (RT) or from non-randomized trials, but not
from multiple RTs nor through consensus expert opinion.
The absence of variation in the level of evidence for each
reconstructive option also implies that there is insufficient
evidence available at this stage to confirm superiority of
one reconstructive method above another. This is the rea-
son why comparison between the various modalities of
treatment available to the surgical team is so difficult. Yet,
it also suggests that some treatment modalities can be rec-
ommended more strongly than others (Class I recommen-
dation) under comparable circumstances. For example
both TNP (only) and a delayed flap come with a Class I
recommendation in cases where the sternum is found to
be fairly stable and viable following an assiduous debride-
ment. This too may complicate determination of the best
treatment option. Both difficulties caused by similarities in
the level of evidence and classification of recommendation
underscore the need for an EB classification as a starting
point from which the best decision can be derived. This
is the ultimate aim of the proposed Classification. Con-
sistent cognizance of the variables should allow com-
parison between treatment that are now regarded to be
either “apples or pears” (for example TNP (only) vs. flap
reconstruction). For example, in our institution our first
choice, in cases with a fairly stable and reasonable viable
bone, would be the application of TNP following a thor-
ough debridement [16]. In other centers, in particular in
the Eastern hemisphere, where TNP is either not avail-
able or popular a flap reconstruction, either with muscle
or omentum would be done [78]. In others again in
others [35,36] muscle flap reconstruction, as a one-step
procedure, is still routinely preferred. Hitherto, com-
parison of the outcomes was difficult.
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left with few options when the sternum is very necrotic
and found to be insufficient for closure following de-
bridement. But then, which flap would be preferable and
at which stage (primary or delayed) should it be applied?
The most difficult cases to decide on (and to compare)
are the scenarios in between the two Types I and 4, be-
cause of the relatively small number of cases per institu-
tion. Comparison could be made easier if some of the
variables are standardized. Eventually it would also open
a way for meta-analysis, which is necessary in small case
series of each institution. The proposed Classification
could be a first step in this direction. What this Classifi-
cation is not primarily intended for is to encourage insti-
tutions to alter their approach to each case of PSM. The
preferred approach to the further management of PSM
is decided on during the first, vigorous debridement that
follows immediately upon diagnosing PSM. Patient-related
factors (hemodynamic stability, sternal bone viability, etc.)
and local circumstances (e.g. availability of material and
expertise) will influence this first decision and determine
the type of management is planned accordingly. It is this
first decision that determines the type of management to
which the patient is allocated. Further treatment may
change according to altering circumstances (e.g. a flap
may be required where initially it was thought unneces-
sary) but the Type will not change – regardless of what
treatment was ultimately given. In this way a prognostic
balance generated from the original treatment allocation is
ensured. Management approach (type) allocation allows
for outcome analysis, which in turn reflects the real-world
clinical scenario because it admits treatment-decision al-
terations and deviations. Insight into the reasons for, and
timing of, these decisions will become clearer. A poten-
tial weakness of the proposed Classification, some may
argue, could be that it is over simplified. This will have
to be weighed against a Classification that is so cumber-
some that it becomes impractical. Time will tell – at
least it is a start.
Conclusion
The development of further, evidence-based guidelines
and research would benefit from universally adopted
classification of the severe infectious process in the
wound that may follow a sternotomy.
In this paper a classification system is introduced
based on Evidence-based principles with the aim of
providing the highest level of evidence currently avail-
able. This system, due to its simplicity, could easily be
adopted provided that there is an early, collaborative
approach between cardiothoracic-, and reconstructive
plastic surgeons. As more evidence becomes available,
undoubtedly the classification proposed here will be
refined. For more evidence, larger numbers, fromnumerous centers internationally, are required and for
this, a classification as presented here, may serve as a
starting as a starting point.
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